Kieback D G, Press M F, Atkinson E N, Edwards G L, Möbus V J, Runnebaum I B, Kreienberg R, Jones L A
Department of Obstetrics & Gynecology, University of Ulm, Germany.
Anticancer Res. 1993 Nov-Dec;13(6B):2489-96.
An Immunoreactive Score (IRS) was compared to the Composition Adjusted Receptor Level (CARL) evaluating prognostic significance of estrogen receptor (ER) expression in 61 ovarian cancers after > or = 8 years. CARL of ER allowed for calculating individual risk curves in stage III and IV, Grade 2 and 3, serous ovarian carcinoma after surgical debulking to < or = 2 cm residual and platinum based chemotherapy. In overall analysis and in subsets defined by tumor stage, grade or a combination thereof significant prognostic distinction became possible using a cutoff IRS of 4 vs. 0 or vs. scores < or = 3. This study substantiates ER as a prognostic variable in human ovarian cancer and for the first time establishes the value of an IRS.
在61例卵巢癌患者随访≥8年后，比较免疫反应评分（IRS）与成分调整受体水平（CARL），以评估雌激素受体（ER）表达的预后意义。ER的CARL可用于计算Ⅲ期和Ⅳ期、2级和3级、手术减瘤至残余灶≤2 cm并接受铂类化疗的浆液性卵巢癌患者的个体风险曲线。在总体分析以及按肿瘤分期、分级或其组合定义的亚组中，使用IRS临界值4与0或与≤3分进行比较时，可实现显著的预后区分。本研究证实ER是人类卵巢癌的一个预后变量，并首次确立了IRS的价值。
